<DOC>
	<DOCNO>NCT01946100</DOCNO>
	<brief_summary>To gather preliminary safety outcome data multimodality treatment lung adenocarcinoma set multifocal BAC .</brief_summary>
	<brief_title>Treatment Multifocal Lung Adenocarcinoma</brief_title>
	<detailed_description>Lung bronchoalveolar carcinoma ( BAC ) adenocarcinoma situ ( AIS ) continue represent poorly understood clinical entity . A frequent clinical dilemma lung cancer care management document suspected invasive adenocarcinoma set multifocal ground glass opacity ( GGO ) consistent multifocal AIS . These patient typically classified stage IV disease , treat palliative chemotherapy . No exist pathologic molecular test currently capable make distinction independent primary versus metastatic tumor , distinction substantial treatment impact exist . Many treat physician suspect outcome specific patient subgroup well norm stage IV disease , patient frequently node-negative without distant metastasis despite multiple lesion present . To address issue , evaluate multimodality treatment protocol use aggressive local target systemic therapy multifocal lung adenocarcinoma , incorporate information tumor genome sequence individualized treatment planning . The result significant impact advance biologic understanding treatment approach lung adenocarcinoma set multifocal AIS .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Patient must &gt; 18 year age Two GGO 's solid lesion suspicious multifocal disease . Clinical diagnosis N0 No evidence distant metastases No prior intrathoracic radiation therapy ( NOTE : Previous radiotherapy part treatment head neck , breast , nonthoracic cancer permit . ) , previous chemotherapy , surgical resection nonsmall cell lung cancer ( NSCLC ) . No cancer past 5 year except early stage prostate cancer , basal cell skin . PFT 's show patient capable tolerate lung resection . Nonpregnant nonlactating . Women childbearing potential must negative urine serum pregnancy test participate study . Patient must able understand willing sign IRBapproved inform consent document .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>multifocal</keyword>
	<keyword>genetic</keyword>
	<keyword>bronchoalveolar carcinoma</keyword>
	<keyword>adenocarcinoma situ</keyword>
	<keyword>ground glass opacity</keyword>
	<keyword>next generation sequence</keyword>
</DOC>